What is the carpet‑track sign in discoid lupus erythematosus and what is the recommended management?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Carpet Track Sign in Discoid Lupus Erythematosus

The carpet-track sign (also called carpet-tack sign) is a pathognomonic clinical finding in discoid lupus erythematosus characterized by whitish filiform papules or spiny projections visible when adherent scales are removed from the lesion, representing follicular plugging that extends into dilated follicular ostia 1.

What the Sign Represents

The carpet-track sign occurs when you peel off the thick, adherent scales from a DLE plaque and observe:

  • Multiple whitish punctate projections on the undersurface of the removed scale
  • Perifollicular whitish halos on the skin surface after scale removal
  • These projections correspond histologically to keratin plugs filling dilated hair follicles (follicular plugging)

This finding is diagnostically valuable because it helps distinguish DLE from other inflammatory, infectious, or neoplastic conditions that may appear similar clinically 1.

Clinical Context

DLE lesions typically present as:

  • Violaceous or erythematous, well-demarcated disc-shaped plaques
  • Thick, adherent whitish scales (where the carpet-track sign can be elicited)
  • Central atrophy and scarring in established lesions
  • Dyspigmentation (hyperpigmentation at borders, hypopigmentation centrally)
  • Permanent scarring alopecia when scalp is involved 1, 2

Recommended Management Algorithm

First-Line Treatment (All Patients)

  1. Photoprotection (essential baseline measure) 3:

    • Avoid direct sun exposure, especially during high UV index days
    • Physical barriers: wide-brimmed hats, sunglasses, long-sleeved clothing
    • Broad-spectrum sunscreen application
  2. Hydroxychloroquine (systemic first-line) 4:

    • Dose: ≤5 mg/kg real body weight daily
    • This is recommended for all lupus patients, including those with cutaneous disease
    • Requires baseline and annual ophthalmologic monitoring after 5 years 5
  3. Topical corticosteroids (potent formulations for localized disease) 4, 3, 6

  4. Topical calcineurin inhibitors (alternative or adjunct to steroids) 4, 3

Second-Line Treatment (Non-Responsive Cases)

When patients fail to respond to antimalarials and topical therapy, or require high-dose glucocorticoids, add immunosuppressive agents 4:

  • Methotrexate (preferred based on guideline hierarchy) 4
  • Mycophenolate 4
  • Retinoids 4, 6
  • Dapsone 4

Emerging Targeted Therapies (Refractory Disease)

For severe, treatment-resistant DLE, newer biologics show promise 2:

  • Anifrolumab (anti-type I interferon receptor)
  • Belimumab (anti-BLiS)
  • Deucravacitinib (TYK2 inhibitor)

Critical Management Principles

Early recognition and prompt treatment are essential to prevent irreversible scarring, permanent alopecia, and disfigurement 1, 6. The carpet-track sign aids in early clinical diagnosis, allowing initiation of therapy before permanent damage occurs.

Avoid systemic glucocorticoids as monotherapy—while they may be used initially, the goal is rapid tapering to <7.5 mg/day prednisone equivalent with transition to steroid-sparing agents 4.

Skin biopsy confirmation should be performed when clinical diagnosis is uncertain, showing characteristic findings: epidermal atrophy, follicular plugging, interface dermatitis, basement membrane thickening, and increased dermal mucin 1, 7.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.